GMED (Globus Medical) Change In Receivables: $-100 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GMED Globus Medical Inc GMED
95 GF Score
Price $74.08
GF Value $97.01
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Globus Medical Change In Receivables?

Globus Medical GMED -0.11% 95 Change In Receivables is $-100 Mil as of Jun. 2026. GuruFocus rates GMED with a GF Score™ of 95/100 and a GF Value™ of $97.01 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Globus Medical's change in receivables for the quarter that ended in Jun. 2026 was $-14 Mil. It means Globus Medical's Accounts Receivable increased by $14 Mil from Mar. 2026 to Jun. 2026 .

Globus Medical's change in receivables for the fiscal year that ended in Dec. 2025 was $-52 Mil. It means Globus Medical's Accounts Receivable increased by $52 Mil from Dec. 2024 to Dec. 2025 .

Globus Medical's Accounts Receivable for the quarter that ended in Jun. 2026 was $692 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Globus Medical's Days Sales Outstanding for the three months ended in Jun. 2026 was 79.99.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Globus Medical's liquidation value for the three months ended in Jun. 2026 was $800 Mil.

Globus Medical  (NYSE:GMED) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Globus Medical's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=692.176/789.612*91
=79.99

2. In Ben Graham's calculation of liquidation value, Globus Medical's accounts receivable are only considered to be worth 75% of book value:

Globus Medical's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=595.142-719.655+0.75 * 692.176+0.5 * 810.897
=800

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Globus Medical Change In Receivables Related Terms

Globus Medical Change In Receivables Historical Data

* Premium members only.

The historical data trend for Globus Medical's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Globus Medical Change In Receivables Chart

Globus Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -25.90 -50.84 -49.91 -78.06 -52.18

Globus Medical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.21 -8.42 -64.15 -13.40 -13.81
GMED
95GF Score
Globus Medical Inc GMED
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Globus Medical Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-100 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $-100 Mil mean?
Globus Medical (GMED) has a Change In Receivables of $-100 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Globus Medical and its competitors.
Is Globus Medical's Change In Receivables too high?
Globus Medical's current Change In Receivables is $-100 Mil. Overall, Globus Medical has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Globus Medical's Change In Receivables compare to GKOS and BIO?
Globus Medical's Change In Receivables of $-100 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Medical Devices & Instruments company?
A good Change In Receivables depends on the Medical Devices & Instruments industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Globus Medical and its competitors. Globus Medical's current Change In Receivables is $-100 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Globus Medical stock overvalued right now?
Based on GuruFocus' analysis, Globus Medical (GMED) is currently considered Modestly Undervalued. The stock's GF Value™ is $97.01, compared to a current price of $74.08 — trading 23.6% below its estimated fair value. The current Change In Receivables is $-100 Mil. Globus Medical's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Globus Medical (GMED), the current Change In Receivables is $-100 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Globus Medical (GMED) Overvalued in 2026?

Based on GuruFocus' analysis, Globus Medical stock appears to be undervalued. The current stock price of $74.08 is trading 23.6% below its estimated GF Value™ of $97.01. GuruFocus considers Globus Medical to be Modestly Undervalued.

Key valuation signals for GMED:

  • Change In Receivables: $-100 Mil
  • GF Value™: $97.01 vs. price of $74.08 (23.6% below fair value)
  • GF Score™: 95/100 with 4 warning signs

No single metric tells the full story. See the GMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Globus Medical Business Description

Other Exchanges GMED:MexicoGM0N:Germany
Address 2560 General Armistead Avenue, Audubon, PA, USA, 19403
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
95GF Score

Get the complete analysis for GMED

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$74.08
Price
$97.01
GF Value